SCHEMBL273530

SCHEMBL273530

Cc1ccc(/C=N/NC(=O)c2cc(Br)ccc2NC(=O)c2cccc(CSc3ccncc3)c2)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.51
POLB P06746 5/20 0.51
NPC1 O15118 5/20 0.47
RAB9A P51151 5/20 0.47
PKM P14618 2/20 0.47
ALDH1A1 P00352 6/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.46
MEN1 O00255 5/20 0.45
KMT2A Q03164 5/20 0.45
SLC34A2 O95436 1/20 0.44
SLC34A1 Q06495 1/20 0.44
SLC34A3 Q8N130 1/20 0.44
SLC20A1 Q8WUM9 1/20 0.44
KDM4E B2RXH2 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
HTT P42858 3/20 0.43
MAPT P10636 3/20 0.43
GAA P10253 1/20 0.43
IDE P14735 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL266695 1.00 LMNA (0.51) LMNAPOLBNPC1RAB9APKM
SCHEMBL267155 0.93 LMNA (0.49) LMNAPOLBNPC1RAB9APKM
SCHEMBL273381 0.93 LMNA (0.49) LMNAPOLBNPC1RAB9APKM
SCHEMBL273386 0.92 POLB (0.48) LMNAPOLBNPC1RAB9APKM
SCHEMBL266993 0.92 POLB (0.48) LMNAPOLBNPC1RAB9APKM
SCHEMBL266977 0.92 POLB (0.51) LMNAPOLBNPC1RAB9APKM
SCHEMBL273681 0.92 POLB (0.51) LMNAPOLBNPC1RAB9APKM
SCHEMBL273398 0.91 MAPT (0.53) LMNAPOLBNPC1RAB9APKM
SCHEMBL267602 0.91 MAPT (0.53) LMNAPOLBNPC1RAB9APKM
SCHEMBL274060 0.88 SLC34A2 (0.57) LMNAPOLBNPC1RAB9APKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 LMNA 1925/4885POLB 3761/4885NPC1 115/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.